329 results on '"Shomali, Navid"'
Search Results
2. Differential effects of docosahexaenoic acid (DHA) and linoleic acid (LA) on miR-101 and miR-342 tumor suppressor microRNAs in Taxol-treated HER2-positive breast cancer cells
3. MicroRNA-155 acts as a potential prognostic and diagnostic factor in patients with ankylosing spondylitis by modulating SOCS3
4. Association of the matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of coronavirus disease 2019 (COVID-19); implications of contribution for development of neurological symptoms in the COVID-19 patients
5. Correction to: association of the matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of coronavirus disease 2019 (COVID-19); implications of contribution for development of neurological symptoms in the COVID-19 patients
6. Pattern-recognition receptors (PRRs) in SARS-CoV-2
7. Dysregulation of miR-193a serves as a potential contributor to MS pathogenesis via affecting RhoA and Rock1
8. MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers
9. Potential anti-inflammatory effect of anti-HMGB1 in animal models of ICH by downregulating the TLR4 signaling pathway and regulating the inflammatory cytokines along with increasing HO1 and NRF2
10. Correction: A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19)
11. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction
12. Emerging role of mesenchymal stromal cells (MSCs)-derived exosome in neurodegeneration-associated conditions: a groundbreaking cell-free approach
13. Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underlying mechanisms, current status, and prospects
14. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
15. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
16. A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19)
17. Correction to: A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19)
18. Immune system-related soluble mediators and COVID-19: basic mechanisms and clinical perspectives
19. Hurdles to breakthrough in CAR T cell therapy of solid tumors
20. A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review
21. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress
22. Correction: Anastasis: cell recovery mechanisms and potential role in cancer
23. Anastasis: cell recovery mechanisms and potential role in cancer
24. CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool
25. Matrix metalloproteinases are involved in the development of neurological complications in patients with Coronavirus disease 2019
26. HSP90 inhibitor modulates HMGA1 and HMGB2 expression along with cell viability via NF-KB signaling pathways in melanoma in-vitro
27. Multi-facets of neutrophil extracellular trap in infectious diseases: Moving beyond immunity
28. miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4
29. Innate and adaptive immune responses against coronavirus
30. Exosomes: Emerging biomarkers and targets in folliculogenesis and endometriosis
31. The emerging role of lncRNAs in multiple sclerosis
32. Frequency of Hepatitis C Virus Genotypes in Patients Who Had Hepatocellular Carcinoma in Gastroenterological Hospitals of Tabriz
33. Prognostic and Diagnostic Values of miR-506 and SPON 1 in Colorectal Cancer with Clinicopathological Considerations
34. Evaluation of the Methylation of MIR129-2 Gene in Gastric Cancer
35. CAR T cells in solid tumors: challenges and opportunities
36. Correction to: Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
37. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
38. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy
39. MicroRNAs as novel biomarkers for colorectal cancer: New outlooks
40. Cancer immunotherapy focusing on the role of interleukins: A comprehensive and updated study
41. New immunotherapeutic approaches for cancer treatment
42. MiR-146a functions as a small silent player in gastric cancer
43. Epigenetic mechanisms shape the underlining expression regulatory mechanisms of the STAT3 in multiple sclerosis disease
44. CANCER THERAPY BY CYCLIN-DEPENDENT KINASE INHIBITORS (CDKIS): BENCH TO BEDSIDE.
45. DETAILED ROLE OF MESENCHYMAL STEM CELL (MSC)- DERIVED EXOSOME THERAPY IN CARDIAC DISEASES.
46. An updated overview of the application of CAR‐T cell therapy in neurological diseases
47. An updated review of a novel method for examining P53 mutations in different forms of cancer
48. Dysregulation of P53 in Breast cancer: Causative factors and treatment strategies
49. Regulatory effect of sericin protein in inflammatory pathways; A comprehensive review
50. MicroRNAs Targeting Programmed Cell Death Protein 1 (PD-1) Promote Natural Killer Cell Exhaustion in Rheumatoid Arthritis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.